Hyundai Bio "Confirms Up to 4-Day Symptom Reduction in Phase 2 COVID-19 Treatment Trial"

Hyundai Bioscience announced on the 13th that the Phase 2 clinical trial results of its COVID-19 treatment candidate 'CP-COV03' confirmed an effect of shortening symptoms by up to 4 days.

Hyundai Bioscience conducted clinical trials of the COVID-19 treatment on 300 adults aged 19 and older at Sinchon Severance Hospital, Korea University Anam Hospital, and other locations. As a result, the primary efficacy endpoint, defined as the period required for 12 COVID-19 symptoms to improve and be maintained for more than 48 hours after administration, was shortened by 4 days in the 300mg dosage group compared to the placebo group. The 450mg dosage group showed only a 0.75-day reduction.

In addition, Hyundai Bioscience stated that no serious adverse reactions to the drug occurred, confirming its safety.

Based on these clinical results, Hyundai Bioscience plans to proceed with global Phase 3 clinical trials and long COVID clinical trials.

This content was produced with the assistance of AI translation services.